Surgery Partners Q2 2026 slides show 5% revenue growth, Idaho exit
Surgery Partners (NASDAQ:SGRY) reported Q2 2026 revenue of $848.9M, above an $830.05M estimate, but posted an adjusted loss of $0.12 per share versus a $0.06 profit expectation. Same-facility revenue grew 5.0% on 4.8% rate growth. The company reaffirmed 2026 guidance: $3.35B to $3.45B revenue and at least $530M adjusted EBITDA, excluding the pending Idaho Falls divestiture.
How this was made
The 30-second read
Why it matters
Investors are likely to reprice the stock around the reaffirmed 2026 revenue and adjusted EBITDA targets, weighing the Q2 adjusted EPS miss against same-facility pricing growth and the expected Medicaid mix improvement from the Idaho Falls sale.
Market read
Q2 revenue beat plus reaffirmed guidance and detailed proforma metrics excluding Idaho Falls create a clear catalyst for re-underwriting the EBITDA growth path, despite an adjusted EPS miss.
What to watch
Adjusted loss vs consensus and the explicit list of regulatory, closing, and litigation risks could outweigh the EBITDA accretion narrative for near-term positioning.
Background
Surgery Partners presented Q2 2026 results alongside a portfolio transformation plan to divest its Idaho Falls market facilities.
Ticker impact
Surgery Partners reported Q2 2026 revenue of $848.9M and reaffirmed 2026 guidance, while detailing the pending Idaho Falls divestiture and its Medicaid mix shift.
Near-term volatility likely, with upside bias if investors focus on the accretive EBITDA/proforma excluding Idaho Falls; downside risk if the adjusted loss and execution/regulatory timing concerns dominate.
The article provides multiple decision-relevant datapoints: Q2 revenue beat, adjusted loss vs profit expectations, reaffirmed full-year revenue and adjusted EBITDA targets, and explicit proforma metrics excluding Idaho Falls plus guidance timing that does not include the sale.
Market effects
Reinforces the ambulatory surgery center theme that pricing strength and physician recruitment can drive same-facility growth even amid Medicaid/provider tax headwinds.
Idaho Falls market exit could shift local service-line capacity and payor mix dynamics, though the article frames it primarily as a portfolio optimization.
Limited, as the story is company-specific and tied to US healthcare reimbursement and regulatory approvals.
Counterpoint
The proforma excluding Idaho Falls may overstate sustainable earnings power if the divestiture timing slips or if Medicaid mix improvement is delayed.
Key entities
- companySurgery Partners
NASDAQ-listed ambulatory surgery center operator reporting Q2 2026 results and reaffirming 2026 guidance while planning an Idaho Falls divestiture.
- assetIdaho Falls market facilities
Planned divestiture described as shifting Medicaid mix lower and removing lower-margin service lines, with stated annualized revenue and EBITDA figures.
